Background The immunosuppressive drug tacrolimus has complex and unpredictable pharmacokinetics, therefore regular monitoring is required in patients receiving tacrolimus therapy. We have developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for measuring tacrolimus concentrations in whole blood and have compared it with a microparticle enzyme immunoassay.
Introduction
Tacrolimus (Prograf, Fujisawa, Munich, Germany) is an immunosuppressive drug which has been shown to be of considerable value in the prevention of graft rejection following solid organ transplantation. 1 Tacrolimus is a macrolide lactone which acts by binding to calcineurin via an immunophilin complex, thereby inhibiting IL2 production. 2 It is metabolized by the liver, and a number of drugs are known to interfere with the cytochrome P450 3A4 primarily responsible for its metabolism. 3 The pharmacokinetics of tacrolimus are complex but it is recognized that trough blood concentrations of the drug are good indicators of systemic exposure, as assessed by pharmacokinetic pro¢les, and can be used to individualize dosage. 4 Therapeutic drug monitoring for tacrolimus is therefore mandatory and because it is highly bound to erythrocytes it is recommended that whole blood samples are used for analysis. 5 There are a number of ways of measuring tacrolimus but enzyme immunoassay methods have proved more popular than chromatographic techniques because of their speed and simplicity. 6 Chromatographic assays are however better at measuring parent drug concentration because they su¡er less with interference from metabolites. There have been a number of high-performance liquid chromatography (HPLC)-based assays reported, including detection with enzyme-linked immunosorbent assay Original Article (ELISA), 7 chemiluminescence 8 and mass spectrometry, 9--11 but it is recognized that only liquid chromatography-tandem mass spectrometry (LC-MS/MS) has the speci¢city for measuring parent drug concentrations. 10 Although LC-MS/MS assays have been developed, they still require relatively large sample volumes and usually need additional sample clean-up procedures. We report here the development and validation of a micro-scale assay for tacrolimus with rapid chromatography.
Materials and methods

Patient samples
The use of patient samples for this study was approved by the local ethical committee. Venous blood samples were collected into Vacutainer tubes (Beckton Dickinson, Oxford, UK) containing EDTA from 99 heart and lung transplant recipients attending the follow-up clinic.
Sample analysis by microparticle-enzyme immunoassay
For comparative purposes, tacrolimus concentrations were measured using microparticle-enzyme immunoassay (MEIA) (Abbott Diagnostics, Maidenhead, UK). Whole blood samples and calibrators were precipitated according to the manufacturer's protocol and then analysed using an IMx analyser (Abbott Diagnostics, Maidenhead, UK).
Internal standards and calibrators
Ascomycin (FR900520) was purchased from Sigma-Aldrich Company Ltd (Poole, UK). Tacrolimus was a gift from Fujisawa (Munich, Germany) and a series of tacrolimus calibrators were also purchased from Abbott Diagnostics. The precipitating solution was prepared by adding ascomycin to acetonitrile to give a concentration of 5¢0 mg/L. A solution of zinc sulphate solution (0¢1mol/L) was prepared for use as a pretreatment solution. Zinc sulphate and HPLC-grade acetonitrile were supplied by VWR International Ltd, Poole, UK.
Sample preparation for liquid chromatography-tandem mass spectrometry
Whole blood samples or calibrators (10 mL) were added to pre-treatment solution (40 mL) in deep well microtitre plates and then precipitating solution (100 mL) was added. The plate was sealed with thermo-sealing ¢lm and vortex-mixed vigorously for 30 s using a multivortex mixer to disperse the precipitated material. After centrifugation at 800 g for 5 min the sealed plate was transferred to the autosampler for analysis.
High-performance liquid chromatography
Chromatography was performed using a Waters 2795 Alliance HT LC system (Waters Ltd, Watford, UK). Supernatant (20 mL) was directly injected from the 96well microtitre plate and was analysed by on-line solidphase extraction using a SecurityGuard C18 cartridge column, 4¢0 mm63¢0 mm (Phenomenex, Maccles-¢eld, UK). The following solvent conditions were used [where Aˆwater containing 2 mmol/ L ammonium acetate and 0¢1% (v/v) formic acid, and Bˆmethanol containing 2 mmol/ L ammonium acetate and 0¢1% (v/v) formic acid]: 50% B for 0 ¢ 4 min, step to 100% B for 0 ¢ 4 min, step back to 50% B to re-equilibrate the column. The run time was set to 1¢4 min to give a cycle time of approximately 2¢5 min injection to injection, thereby allowing a total re-equilibration time of approximately 1¢7 min. The column was maintained at 558C and the eluent was connected directly to the electrospray probe of the mass spectrometer with no splitting or solvent diversion.
Mass spectrometry
A Quattro micro 2 tandem mass spectrometer ¢tted with a Z Spray ion source was used for all analyses (Micromass, Manchester, UK). The instrument was operated in electrospray positive ionization mode and was directly coupled to the HPLC system. System control and data acquisition were performed with MassLynx NT 3.5 software with automated data processing using the MassLynx QuanLynx programme provided with the mass spectrometer. Calibration curves were constructed using linear least squares regression, and 1/x weighting was used to ensure maximum accuracy at the lower tacrolimus concentrations.
To tune the mass spectrometer, a solution of tacrolimus or ascomycin (10 mmol/L) in 50% aqueous methanol containing 2 mmol/ L ammonium acetate and 0¢1% formic acid was infused into the ion source, and the cone voltage optimiz ed to maximize the intensity of the (M+NH 4 ) + precursor ions for tacrolimus and ascomycin (m/z 821 and 809, respectively). The collision energy was then adjusted to optimize the signal for the most abundant product ions (m/z 768 and 756, respectively). Typical tuning conditions were as follows: electrospray capillary voltage 1¢0 kV, sample cone voltage 25 V, and collision energy 22 eV at a collision gas pressure 1 ¢ 8610 73 mBar argon. Sample analyses were performed in the multiple reaction monitoring (MRM) mode of the mass spectrometer with a dwell time of 0¢25 s per channel using the following transitions; m/z8214768 (tacrolimus) and m/z8094756 (ascomycin).
Results
Sample preparation using aqueous zinc sulphate followed by acetonitrile resulted in a clear, colourless supernatant that gave clean chromatograms with no interfering compounds present (see Fig. 1 ). Elution of ascomycin (0¢98 min) and tacrolimus (0¢98 min) allowed an injection-to-injection cycle time of 2 ¢ 5 min.
Quantitation was performed by integrating the area under the extracted ion chromatograms for tacrolimus and internal standard for a series of whole blood calibrators. A calibration curve was constructed by plotting the tacrolimus/ internal standard peak area ratio against tacrolimus concentration (see Fig. 2 ). The curve was linear over the calibration range up to 30 mg/L and showed a good correlation with the stated values for the calibrators (R 2ˆ0 ¢9986, yˆ0 ¢021 x+0 ¢005). The limit of detection was 0 ¢ 01 mg/L [2 ¢ 56standard deviation (SD) of zero calibrator] and the limit of quantitation, derived from the precision pro¢le curve, was 0¢5 mg/L (see Fig. 3 ).
The stability of the extracted materials in the supernatant was tested by repeated injections of the extract from a pooled sample. 20 mL injections were made every 10 min over a 27-h period. No systematic loss in sensitivity for either tacrolimus or ascomycin was observed in the absolute peak areas measured, and the coe¤cient of variation (CV) for peak area ratio (analyte/internal standard) was 2¢9% (see Fig. 4 ).
The within-day and between-day precision for tacrolimus, assessed on three separate pools, is shown in Table 1 . The pools were made from samples routinely analysed for tacrolimus within our laboratory and the same pools were used for both within-and betweenday analyses. Within-day precision (CV57%) and between-day precision (CV56%) were both acceptable but we found the between-day precision to be slightly better than the within-day precision. The assay for within-day precision contained several poor data points which contributed to less than optimal precision, but we nevertheless decided to report these results because the CV was still acceptable.
The mean recovery of tacrolimus across a range of concentrations between 2¢0 and 23¢0 mg/L was 109%, In order to examine any suppression of ionization, a series of six whole blood samples was spiked with tacrolimus at concentrations of 5, 10 and 20 mg/L and prepared in the standard way. In addition, a series of aqueous standards was prepared in triplicate at identical concentrations. The area counts for the internal standard (ascomycin) and tacrolimus for the whole blood and aqueous samples are shown in Table 2 , together with the tacrolimus:internal standard ratios. There was no di¡erence in the area counts or the ratios between whole blood sample results and aqueous tacrolimus solution results, indicating that there was no evidence of ion suppression. Comparison of the tacrolimus concentration measured in the samples from 99 heart and lung transplant recipients by MEIA and LC-MS/MS showed good agreement between the two methods (see Fig. 5 ) and con¢rmed the expected negative bias of the LC-MS/ MS assay due to its higher speci¢city. single point calibration would su¤ce for result processing. The 30 mg/L calibrator was chosen as the single point and the calibration line was forced through zero. Analysis by paired T test showed that there was no signi¢cant di¡erence between the results calculated by either single-or multiple-point calibration, Pˆ0 ¢32. The regression line showed single point calibrationˆ0¢998(multiple point calibration)+0¢03, R 2ˆ0 ¢999. In addition, a Bland Altman di¡erence plot showed no signi¢cant bias between the two methods of calibration (see Fig. 6 ).
Discussion
At low collision energy protonated tacrolimus and ascomycin are resistant to fragmentation, whilst at higher energy many fragments of low intensity are formed. Maximum sensitivity was therefore obtained by monitoring fragmentation of the tacrolimus and ascomycin ammonium adducts (M+NH 4 ) + which form major product ions. 
Bland Altman difference plot of tacrolimus concentrations measured by liquid chromatography--tandem mass spectometry using single or multiple point calibration.
In this assay, the use of a relatively crude sample extract was facilitated by the combination of on-line solid phase extraction and detector speci¢city. The limited chromatography provided by the small cartridge column nevertheless removes ion suppressive components e¡ectively and the detector speci¢city allows simultaneous measurement of superimposed peaks. We have also demonstrated that the injection of relatively large amounts of extract (20 mL) does not foul up the detector, as we did not see a decrease in the detector response over a 27-h period. This is largely due to the dual-orthogonal design of the ion source, which diverts contaminants away from sensitive parts of the instrument.
We found reasonable agreement between the LC-MS/ MS method and the IMX assay, but agreement with assigned values from IPT samples was better. This con¢rms the excellent accuracy of the method and also con¢rms the view that there is cross-reactivity with metabolites in the IMX assay. Our results show that lengthy sample clean-up procedures are not necessary and that the use of crude sample extracts provides the required accuracy and precision.
We used ascomycin as an internal standard, in keeping with other methods, 10 because it is a structural analogue of tacrolimus and should therefore behave in a similar manner during processing.
The use of deep-well microtitre plates which ¢t directly onto the autosampler allowed us to process and inject samples without having to transfer into autosampler vials. Judicious positioning of the injector needle prevented contamination from the protein precipitate formed during the sample preparation. Using this procedure, 24 samples can be processed and ready for injection onto the LC-MS/ MS within 30 min. This has saved processing time and also provides further scope for automation. Reducing sample transfer steps also signi¢cantly reduces the chance of error. Assay time, and hence result turnaround, was further reduced by decreasing the chromatography time. This resulted in injection-toinjection times of 2 ¢ 5 min and enabled the processing of 24 samples per hour, including result generation.
Blood-based standards produced in the laboratory using weighed-in tacrolimus have traditionally been used as calibrators, but we found that commercially available calibrators designed for immunoassays produce good results with the LC -MS/MS procedure. In addition, we demonstrated that the assay can be successfully calibrated using only one calibrator. This will be advantageous to laboratories unable to make their own calibrators and will further save processing and analysis time.
We developed the use of a small sample size, which should prove useful when monitoring paediatric patients and will also be sparing of expensive cali-brator and quality control (QC) materials. It should also make it possible to use capillary blood from ¢nger prick collection, a sample method which has already been validated for cyclosporin A analysis 12 but which would need further investigation and validation for tacrolimus quanti¢cation. The LC-MS/MS assay has several advantages over the MEIA method, namely, better speci¢city for the parent compound, improved assay sensitivity, the facility for larger batch sizes to be run and there is no interference from haemolysed samples.
Conclusion
We have developed an LC-MS/MS method for the measurement of tacrolimus which is quick, precise and robust and which will provide a fast turnaround of results, to aid the transplant physician.
